ReviewEndocrinology, diabetes & metabolism2026
Implications of Genetic Elements on Type 2 Diabetes Mellitus Pathogenesis and Management.
Review in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a complex, multifactorial disease influenced by interactions between environmental exposures and genetic determinants. Increasing evidence highlights the important role of genetic variation in disease susceptibility, progression, and therapeutic response.
aimThis review aims to explore key genetic factors associated with T2DM risk and pathogenesis, as well as pharmacogenomic variants that influence antidiabetic therapy metabolism and clinical response.
resultsSeveral genetic variants have been linked to altered glucose metabolism and increased susceptibility to T2DM. Notable genes include KCNJ11, HNF4A, IGF2BP2, CDKN2A/B, PPARγ, KLF14, and IRS, which influence insulin secretion, insulin signalling, and glucose regulation. Genetic polymorphisms vary across populations and may contribute to differences in disease susceptibility. In addition, variations in drug-metabolising enzymes, particularly within the cytochrome P450 enzymes (CYP450), can influence the pharmacokinetics and pharmacodynamics of commonly prescribed antidiabetic medications. Some major CYP450 isoforms implicated in the metabolism of antidiabetic medications have been shown to exhibit polymorphisms that can alter plasma drug concentrations, ultimately leading to poor glycaemic control or heightening adverse effects.
conclusionTherefore, understanding these genetic underpinnings is critical for advancing precision medicine approaches in diabetes care, enabling tailored pharmacotherapy and optimising treatment outcomes. By integrating genetic insights into clinical decision-making, this paper highlights the potential of pharmacogenomics not only to identify populations at risk of developing T2DM but also to improve glycaemic control, reduce adverse drug reactions, and enhance patients' quality of life with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.